339 related articles for article (PubMed ID: 23672678)
21. Predictive Value of
Song BI; Kim HW; Won KS
Ann Surg Oncol; 2017 Aug; 24(8):2174-2181. PubMed ID: 28432480
[TBL] [Abstract][Full Text] [Related]
22. Additional Prone 18F-FDG PET/CT Acquisition to Improve the Visualization of the Primary Tumor and Regional Lymph Node Metastases in Stage II/III Breast Cancer.
Teixeira SC; Koolen BB; Vogel WV; Wesseling J; Stokkel MP; Vrancken Peeters MJ; van der Noort V; Rutgers EJ; Valdés Olmos RA
Clin Nucl Med; 2016 Apr; 41(4):e181-6. PubMed ID: 26704731
[TBL] [Abstract][Full Text] [Related]
23. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer.
Crippa F; Agresti R; Seregni E; Greco M; Pascali C; Bogni A; Chiesa C; De Sanctis V; Delledonne V; Salvadori B; Leutner M; Bombardieri E
J Nucl Med; 1998 Jan; 39(1):4-8. PubMed ID: 9443729
[TBL] [Abstract][Full Text] [Related]
24. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures.
Fuster D; Duch J; Paredes P; Velasco M; Muñoz M; Santamaría G; Fontanillas M; Pons F
J Clin Oncol; 2008 Oct; 26(29):4746-51. PubMed ID: 18695254
[TBL] [Abstract][Full Text] [Related]
25. The value of 18-FDG PET/CT in early-stage breast cancer compared to traditional diagnostic modalities with an emphasis on changes in disease stage designation and treatment plan.
Garami Z; Hascsi Z; Varga J; Dinya T; Tanyi M; Garai I; Damjanovich L; Galuska L
Eur J Surg Oncol; 2012 Jan; 38(1):31-7. PubMed ID: 21937190
[TBL] [Abstract][Full Text] [Related]
26. Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers.
Ulaner GA; Goldman DA; Gönen M; Pham H; Castillo R; Lyashchenko SK; Lewis JS; Dang C
J Nucl Med; 2016 Sep; 57(9):1350-6. PubMed ID: 26940766
[TBL] [Abstract][Full Text] [Related]
27. Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients.
Riegger C; Herrmann J; Nagarajah J; Hecktor J; Kuemmel S; Otterbach F; Hahn S; Bockisch A; Lauenstein T; Antoch G; Heusner TA
Eur J Nucl Med Mol Imaging; 2012 May; 39(5):852-63. PubMed ID: 22392069
[TBL] [Abstract][Full Text] [Related]
28. Dual time point FDG-PET/CT imaging... Potential tool for diagnosis of breast cancer.
Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E
Clin Radiol; 2008 Nov; 63(11):1213-27. PubMed ID: 18929039
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of FDG-PET/CT at the postoperative surveillance in the breast cancer patients.
Jung NY; Yoo IR; Kang BJ; Kim SH; Chae BJ; Seo YY
Breast Cancer; 2016 Jan; 23(1):141-148. PubMed ID: 24872087
[TBL] [Abstract][Full Text] [Related]
30. [Diagnostic and therapeutic impact of 18F-FDG-PET/CT in patients with suspected breast cancer recurrence].
Palomar Muñoz A; García Vicente AM; Talavera Rubio MP; Pilkington Woll JP; Poblete García VM; Bellón Guardia ME; León Martín A; Cordero García JM; Soriano Castrejón A
Rev Esp Med Nucl; 2010; 29(3):100-8. PubMed ID: 20392542
[TBL] [Abstract][Full Text] [Related]
31. [Value of fused 18F-FDG PET/CT images in predicting efficacy of neoadjuvant chemotherapy on breast cancer].
Li D; Chen JH; Wang J; Ling R; Yao Q; Wang L
Ai Zheng; 2007 Aug; 26(8):900-4. PubMed ID: 17697556
[TBL] [Abstract][Full Text] [Related]
32. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography combined with ultrasonography-guided fine needle aspiration cytology for identifying axillary lymph node status in patients with breast cancer.
Machida Y; Kubota K; Katayama T; Toriihara A; Shibuya H
Eur J Surg Oncol; 2013 Jan; 39(1):26-30. PubMed ID: 23122913
[TBL] [Abstract][Full Text] [Related]
34. ¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer.
Groheux D; Hindié E; Marty M; Espié M; Rubello D; Vercellino L; Bousquet G; Ohnona J; Toubert ME; Merlet P; Misset JL
Eur J Radiol; 2014 Oct; 83(10):1925-33. PubMed ID: 24985086
[TBL] [Abstract][Full Text] [Related]
35. 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer.
van der Hoeven JJ; Krak NC; Hoekstra OS; Comans EF; Boom RP; van Geldere D; Meijer S; van der Wall E; Buter J; Pinedo HM; Teule GJ; Lammertsma AA
J Clin Oncol; 2004 Apr; 22(7):1253-9. PubMed ID: 15051773
[TBL] [Abstract][Full Text] [Related]
36. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
37. 18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer.
Song BI; Lee SW; Jeong SY; Chae YS; Lee WK; Ahn BC; Lee J
J Nucl Med; 2012 Sep; 53(9):1337-44. PubMed ID: 22870824
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer.
Ueda S; Tsuda H; Asakawa H; Shigekawa T; Fukatsu K; Kondo N; Yamamoto M; Hama Y; Tamura K; Ishida J; Abe Y; Mochizuki H
Jpn J Clin Oncol; 2008 Apr; 38(4):250-8. PubMed ID: 18407934
[TBL] [Abstract][Full Text] [Related]
39. The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques.
Aukema TS; Rutgers EJ; Vogel WV; Teertstra HJ; Oldenburg HS; Vrancken Peeters MT; Wesseling J; Russell NS; Valdés Olmos RA
Eur J Surg Oncol; 2010 Apr; 36(4):387-92. PubMed ID: 19962268
[TBL] [Abstract][Full Text] [Related]
40. Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer.
Groheux D; Hindié E; Delord M; Giacchetti S; Hamy AS; de Bazelaire C; de Roquancourt A; Vercellino L; Toubert ME; Merlet P; Espié M
J Natl Cancer Inst; 2012 Dec; 104(24):1879-87. PubMed ID: 23243198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
